Tuesday, July 11, 2017 7:10:19 PM
Assume they do a 100-1 reverse split in order to uplist. Now they will have 4 million shares outstanding however, now you'll only have a hundredth of what you had prior to the split. Example, I'll give you my current investment in Oxis. I currently have 130,000 shares at a price of $0.074 per share. After the split I'll now have 1,300 shares at a price of $7.4 per share. Assuming after the up list they sell an additional 56 million shares. They will now have 60 million outstanding (4 million from the reverse split plus 56 million from the ipo). As long as the stock price stays at or above $7.40 with a market cap of 444 million. I'm okay. Anything below that, I'm losing money.
So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.
The reason they won't have anywhere near 750 million after the split, is because then they remain a penny stock. (In order for them to not be a penny stock with 750 million shares outstanding, they'd need a price per share of $5.00 which would assume a 3.75 billion market cap.) Which until they at the very least have a phase three trial ongoing or NDA is highly unlikely.
So again my answer is I think there will be a total of 60 million shares outstanding after the reverse split.
Worst case scenario, 100 million, but remember this is after the reverse split.
Kite Pharma: 57 million source NASDAQ
Juno Therapeutics : 106 million outstanding source NASDAQ
Bluebird Bio: 41 million outstanding source NASDAQ
Recent GTBP News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 05:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 08:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 10:00:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:25:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/06/2023 10:23:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/06/2023 10:21:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/01/2023 01:00:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 09:23:48 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/19/2023 03:56:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:29:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 11:26:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 01:00:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM